742104-68-3

Upstream product

• 7409-30-5 p-nitrobenzylamine 
• 4403-71-8 (4-aminomethyl)aniline 
• 742104-57-0 KYS₀₅₀₃₄ 
• 612-41-9 2-nitrocinnamic acid 
• 659748-14-8 methyl 3-[2-(3-phenylureido)phenyl]acrylate 
• 200571-81-9 (3-Phenyl-2-piperidin-1-yl-3,4-dihydro-quinazolin-4-yl)-acetic acid 
• 174534-47-5 4-methoxycarbonylmethyl-2-(1-piperidinyl)-3-phenyl-3,4-dihydroquinazoline 
• 139210-05-2 methyl 3-[2-(phenyliminomethyleneamino)phenyl]acrylate 
• 88939-75-7 methyl (2E)-3-(2-aminophenyl)propenoate 
• 39228-29-0 (E)-methyl 2-nitrocinnamate 

Relevant academic research and scientific papers

T-type Ca2+ channel blockers suppress the growth of human cancer cells

In order to further clarify the role of T-type Ca2+ channels in cell proliferation, we have measured the growth inhibition of human cancer cells by using our potent T-type Ca2+ channel blockers. As a result, KYS05090, a most potent T-type Ca2+ channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. Therefore, this letter provides the biological results that T-type calcium channel is important in regulating the important cellular phenotype transition leading to cell proliferation, and thus novel T-type Ca2+ channel blocker presents new prospects for cancer treatment.

Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers

This paper describes the preliminary biological results that novel T-type calcium channel blockers inhibit the growth of human cancer cells by blocking calcium influx into the cell, based on unknown mechanism on the cell cycle responsible for cellular proliferation. Among the selected compounds from compound library, compound 9c (KYS05041) was identified to be nearly equipotent with Cisplatin against some human cancers in the micromolar range.

Synthesis and SAR studies of a novel series of T-type calcium channel blockers

For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among the

3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same

The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihyd

3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same

The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihyd

3,4-Dihydroquinazoline derivatives as novel selective T-type Ca 2+ channel blockers

For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS0